Q1 Earnings Estimate for Zymeworks Issued By Lifesci Capital

Zymeworks Inc. (NASDAQ:ZYME) – Equities research analysts at Lifesci Capital dropped their Q1 2026 earnings per share (EPS) estimates for Zymeworks in a research note issued on Monday, March 2nd. Lifesci Capital analyst C. Zhu now expects that the company will earn ($0.52) per share for the quarter, down from their previous estimate of $0.55. Lifesci Capital also issued estimates for Zymeworks’ Q2 2026 earnings at ($0.49) EPS, Q3 2026 earnings at $0.84 EPS, Q4 2026 earnings at ($0.50) EPS and FY2026 earnings at ($0.68) EPS.

Zymeworks (NASDAQ:ZYME) last announced its quarterly earnings data on Monday, March 2nd. The company reported ($0.55) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.20). Zymeworks had a negative net margin of 76.56% and a negative return on equity of 26.00%. The business had revenue of $2.52 million during the quarter, compared to the consensus estimate of $21.78 million. During the same period last year, the company earned ($0.31) EPS. The business’s revenue was down 91.9% compared to the same quarter last year.

Several other equities research analysts have also recently issued reports on the stock. Wells Fargo & Company raised shares of Zymeworks from an “equal weight” rating to an “overweight” rating and boosted their price objective for the company from $25.00 to $33.00 in a research report on Friday, December 12th. Leerink Partners boosted their price target on Zymeworks from $52.00 to $58.00 and gave the company an “outperform” rating in a report on Tuesday. Citizens Jmp set a $32.00 price objective on Zymeworks in a report on Wednesday, December 3rd. Citigroup started coverage on Zymeworks in a research report on Wednesday, December 3rd. They set an “outperform” rating for the company. Finally, Truist Financial initiated coverage on Zymeworks in a research report on Wednesday, December 17th. They set a “buy” rating and a $40.00 price target on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $35.70.

Zymeworks Trading Up 3.2%

NASDAQ ZYME opened at $25.23 on Thursday. The stock has a market cap of $1.86 billion, a PE ratio of -23.36 and a beta of 1.23. Zymeworks has a 12 month low of $9.03 and a 12 month high of $28.49. The company’s 50-day moving average price is $23.82 and its 200-day moving average price is $20.98.

Institutional Trading of Zymeworks

A number of institutional investors have recently modified their holdings of ZYME. EcoR1 Capital LLC grew its position in shares of Zymeworks by 33.1% in the 2nd quarter. EcoR1 Capital LLC now owns 22,970,388 shares of the company’s stock worth $288,278,000 after buying an additional 5,710,840 shares during the last quarter. Siren L.L.C. acquired a new stake in Zymeworks in the fourth quarter valued at approximately $44,238,000. Perceptive Advisors LLC grew its holdings in Zymeworks by 56.0% in the fourth quarter. Perceptive Advisors LLC now owns 3,261,850 shares of the company’s stock worth $85,885,000 after purchasing an additional 1,171,187 shares during the last quarter. Rubric Capital Management LP increased its position in shares of Zymeworks by 22.1% during the fourth quarter. Rubric Capital Management LP now owns 5,750,000 shares of the company’s stock worth $151,398,000 after purchasing an additional 1,039,449 shares in the last quarter. Finally, Capricorn Fund Managers Ltd acquired a new position in shares of Zymeworks during the fourth quarter worth $26,931,000. 92.89% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other Zymeworks news, EVP Jeffrey T. L. Smith sold 9,310 shares of the stock in a transaction on Monday, January 12th. The stock was sold at an average price of $22.67, for a total transaction of $211,057.70. Following the sale, the executive vice president owned 26,708 shares of the company’s stock, valued at approximately $605,470.36. This trade represents a 25.85% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Kenneth Galbraith sold 30,424 shares of the business’s stock in a transaction on Monday, January 12th. The stock was sold at an average price of $22.67, for a total value of $689,712.08. Following the completion of the transaction, the chief executive officer directly owned 226,842 shares of the company’s stock, valued at approximately $5,142,508.14. The trade was a 11.83% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 187,933 shares of company stock worth $4,673,716 in the last three months. Corporate insiders own 33.51% of the company’s stock.

Key Zymeworks News

Here are the key news stories impacting Zymeworks this week:

• Positive Sentiment: Stifel Nicolaus raised its price target to $47 and kept a Buy rating, giving investors a higher upside view versus the current price. Stifel Boosts Price Target
• Positive Sentiment: Leerink Partners bumped its target to $58 and maintained an Outperform stance, signaling strong upside expectations that likely helped lift sentiment. Leerink Raises Target
• Positive Sentiment: Lifesci Capital sharply improved its FY2026 EPS forecast (from about -$1.40 to -$0.68) and raised Q2–Q4 estimates, suggesting research analysts see a path to reduced losses (despite a weaker Q1). This upward revision supports the more bullish analyst narrative. Lifesci Capital Model Revisions
• Neutral Sentiment: Analysis notes improved liquidity (about $270.6M cash) and a $250M royalty financing with Royalty Pharma that extends runway beyond 2028—reducing near-term dilution risk but increasing reliance on Ziihera’s commercial performance. FY25 Review
• Negative Sentiment: Q4 2025 results were weak: EPS missed and revenue collapsed to $2.52M (vs. ~$21.8M est), a ~92% y/y decline—a reminder of milestone-driven volatility and execution risk that could pressure shares if commercial traction slips. Q4 Earnings Call Summary
• Negative Sentiment: Coverage warns that Zymeworks’ outlook hinges on zanidatamab’s clinical/commercial success; heavy dependence on a single program raises binary risk despite improved analyst sentiment. Zanidatamab Reliance

Zymeworks Company Profile

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. The company specializes in engineered antibody and protein therapeutics designed to address a range of unmet medical needs in oncology and other serious diseases. Through its proprietary platforms, Zymeworks aims to create novel bispecific and multispecific molecules that can simultaneously engage multiple targets and recruit immune effector functions to enhance potency and specificity.

At the core of Zymeworks’ innovation is its Azymetric™ bispecific antibody platform, which enables the design of asymmetrical bispecific antibodies with controlled assembly and high stability.